Refractive Outcomes Of A Retrospective Cohort Study On The Edof Elon® Implant.

Cataract surgery benefits from constant innovations, particularly in the design of intraocular lenses (IOLs), to provide patients with the most comfortable postoperative vision possible while maximizing their independence from optical corrections. Elon® (MEDICONTUR) is a non-diffractive Extended Depth-of-Focus (EDoF) implant, made of hydrophobic acrylic, utilizing wavefront shaping technology. This study aims to evaluate the refractive outcomes and quality of life of patients after phacoemulsification and implantation of this lens.

This is a monocentric, retrospective, non-comparative study on Elon® implants placed between January and December 2024 at the Fondation Rothschild Hospital (Paris, France). 

Postoperative outcomes were analyzed three months after surgery, assessing monocular and binocular corrected and uncorrected visual acuity (VA) at 30 cm, 66 cm, and 5 m, the defocus curve of the implant, as well as contrast sensitivity (CS) and patients functional perception through a quality-of-life questionnaire. Adverse effects of the implant, such as halos or glare, were also evaluated.

TBD

The Elon® implant provides good visual acuity and independence from glasses for both distance and intermediate vision, while reducing unwanted optical phenomena compared to traditional multifocal implants. However, it remains insufficient to ensure good near vision without optical correction.